Form 4: Blueprint Medicines Chief Scientific Officer Sells Shares to Cover Tax Obligations

Percy H. Carter, Chief Scientific Officer and Director of Blueprint Medicines Corp, sold 2,659 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Summary

• Percy H. Carter, Chief Scientific Officer and Director of Blueprint Medicines Corp (BPMC), sold a total of 2,659 shares of common stock.
• The sales occurred on June 3, 2025, at a price of $127.88 per share.
• Specifically, two transactions took place: 241 shares were sold, followed by 2,418 shares.
• Following these transactions, Mr. Carter beneficially owns 54,206 shares of common stock.
• The sales were non-discretionary, executed automatically as "sell to cover" transactions to satisfy tax withholding obligations arising from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a routine "sell to cover" to satisfy tax obligations from RSU vesting, not a discretionary sale, thus indicating a neutral sentiment regarding the insider's view of the company's future prospects.

Positives

• The transaction is a non-discretionary "sell to cover" to meet tax obligations, indicating it's not a reflection of negative sentiment towards the company by the insider.
• The insider, Percy H. Carter, still retains a significant beneficial ownership of 54,206 shares of common stock, demonstrating continued alignment with shareholder interests.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Management Comments

• "The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units."
• "The sale occurred automatically to satisfy the tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person."

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitors. Such transactions are routine for executives receiving equity compensation.

Comparison to Industry Standards

• This document, an SEC Form 4, reports an insider stock transaction (a "sell to cover" for tax purposes). It does not contain information that allows for a comparison to global benchmarks, specific comparable companies, projects, or results. Such comparisons are typically found in financial statements (10-K, 10-Q) or earnings reports.

Related Party Transactions

• The reported transaction is an insider sale by an officer and director, which is a type of related party transaction. However, it is specifically for tax withholding purposes related to equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a non-discretionary tax-related sale, not indicative of a change in insider confidence. The number of shares sold is relatively small compared to the total outstanding shares.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Blueprint Medicines Corp, BPMC, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Sell to Cover, Percy H. Carter, Chief Scientific Officer